Change search
ReferencesLink to record
Permanent link

Direct link
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers
Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark..
St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland..
Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark..
Univ Med, Ctr Utrecht, Dept Gynecol Oncol, Utrecht, Netherlands..
Show others and affiliations
2016 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 26, no 1, 43-51 p.Article in journal (Refereed) PublishedText
Abstract [en]

Objective:To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial varian cancer. Methods: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. Results: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. Conclusions: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.

Place, publisher, year, edition, pages
2016. Vol. 26, no 1, 43-51 p.
Keyword [en]
Ovarian cancer, CA125, HE4, Screening, Differential diagnosis, Monitoring
National Category
Cancer and Oncology Obstetrics, Gynecology and Reproductive Medicine
URN: urn:nbn:se:uu:diva-275569DOI: 10.1097/IGC.0000000000000586ISI: 000367537300006PubMedID: 26588231OAI: diva2:900469
Available from: 2016-02-04 Created: 2016-02-04 Last updated: 2016-02-04Bibliographically approved

Open Access in DiVA

fulltext(276 kB)154 downloads
File information
File name FULLTEXT01.pdfFile size 276 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Tholander, Bengt
By organisation
Experimental and Clinical Oncology
In the same journal
International Journal of Gynecological Cancer
Cancer and OncologyObstetrics, Gynecology and Reproductive Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 154 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 718 hits
ReferencesLink to record
Permanent link

Direct link